Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Otolaryngol ; 43(6): 103609, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36029619

RESUMO

INTRODUCTION: Actinomycosis is a granulomatous infection that rarely involves the larynx or pharynx. Three cases of actinomycosis of the larynx or pharynx from our institution were reviewed and a systematic literature review was performed to better define surgical management, antibiotic therapy, risk factors, and incidence of recurrence or complications. MATERIALS AND METHODS: PubMed/Medline, Cochrane, Embase, and Google Scholar were searched on November 30, 2021 using the terms "laryngeal actinomycosis", "pharyngeal actinomycosis", "actinomycosis AND larynx", and "actinomycosis AND pharynx." Articles which did not describe appropriate sites or were non-English were excluded. Results were collected for demographic information, site(s) of infection, comorbidities, lesion characteristics and treatments. RESULTS: Along with three cases reported from our institution, 40 unique cases were reviewed from 37 studies for a total of 43 patients (Table 1). 34 (81.0 %) of the patients were male with the highest incidence of infection in the seventh decade (54.8 %). The most common site for the infection was the larynx (69.0 %) followed by the pharynx (16.7 %). Risk factors included a history of radiation therapy, immunosuppression, inhalational irritant, and diabetes (Table 3). The duration of antibiotic therapy varied greatly, from one month to one year and total follow up ranged from 1 month to 2.5 years (Table 1). CONCLUSIONS: A comprehensive review of the literature on pharyngolaryngeal actinomycosis shows that this infection has increased prevalence within the head and neck cancer patient population. Similar to cervicofacial actinomycosis, these atypical sites have shown favorable responses to extended antibiotic therapy and generally do not require aggressive surgical management.


Assuntos
Actinomicose , Laringe , Humanos , Masculino , Feminino , Faringe/patologia , Irritantes , Actinomicose/terapia , Actinomicose/tratamento farmacológico , Laringe/patologia , Antibacterianos/uso terapêutico
2.
Am J Surg Pathol ; 43(7): 885-897, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31021855

RESUMO

Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy, but categorization is complicated by variability in grading systems and uncertain prognostic significance of MAML2 rearrangement. The aims of this study were to determine the prognostic significance of MEC grading systems and MAML2 rearrangement status. Fifty-three carcinomas originally diagnosed as MEC (45 primary; 8 recurrent) of major and minor salivary glands were graded according to modified Healey, Brandwein, AFIP, and Katabi systems. Fluorescence in situ hybridization for MAML2 rearrangement was performed. Clinical features and outcomes were recorded. Twenty-five (47%) carcinomas scored the same in all grading systems. The most common histologic feature leading to a diagnosis of intermediate grade was isolated solid growth. Brandwein assigned the highest percentage of high grade (29%) and AFIP the highest percentage of low grade (80%). MAML2 was rearranged in 37/46 (80%) cases. Forty-three (81%) were morphologically compatible with MEC, and these were more likely to be low-intermediate grade and MAML2-rearranged. Of primary carcinomas, 6 (13%) recurred. Statistically significant univariate risk factors for recurrence included non-MEC morphology, stage T4, and high Brandwein grade. Margin status, MAML2 rearrangement, and isolated solid growth were not predictive of recurrence. A binary grading system (Brandwein high vs. low-plus-intermediate) could be considered to better reflect biological behavior in MEC. Our study confirms that MAML2 wildtype tumors more likely represent high grade non-MECs, and prior studies demonstrating worse prognosis in MAML2-nonrearranged MECs may be diluted by high-grade non-MECs.


Assuntos
Biomarcadores Tumorais/genética , Carcinoma Mucoepidermoide/genética , Carcinoma Mucoepidermoide/patologia , Rearranjo Gênico , Gradação de Tumores/métodos , Neoplasias das Glândulas Salivares/genética , Neoplasias das Glândulas Salivares/patologia , Transativadores/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Mucoepidermoide/mortalidade , Carcinoma Mucoepidermoide/cirurgia , Criança , Feminino , Predisposição Genética para Doença , Humanos , Hibridização in Situ Fluorescente , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Valor Preditivo dos Testes , Fatores de Risco , Neoplasias das Glândulas Salivares/mortalidade , Neoplasias das Glândulas Salivares/cirurgia , Fatores de Tempo , Adulto Jovem
4.
Otolaryngol Head Neck Surg ; 145(5): 759-66, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21750345

RESUMO

OBJECTIVE: To find the survival rate of patients ≥ 80 years old who undergo salvage surgery for squamous cell carcinoma of the larynx. STUDY DESIGN: National data registry analysis. SETTING: Seventeen population-based registries comprising the National Cancer Institute's Surveillance, Epidemiology, and End Results database. SUBJECTS AND METHODS: Overall, cancer-specific, and relative survival rates were calculated from 1418 patients, stratified into 3 age cohorts, who underwent surgery following radiation therapy for treatment of laryngeal cancer. RESULTS: The 1-year overall survival of patients ≥ 80 years old (n = 57) was 76.1%. The cancer-specific survival at 1 year was 86.4%. These survival rates were significantly less than those of patients <65 years old (n = 869), who had a 1-year overall survival of 88.1% (P = .006) and cancer-specific survival of 90.5% (P = .029). Patients aged between 65 and 79 years old (n = 492) displayed 1-year overall survival of 80.7% (P = .426) and cancer-specific survival of 85.1% (P = .711), which were not significantly different from the ≥ 80 year cohort. When comparing relative survival at 5 years, the ≥ 80-year-old cohort's survival trended the highest (≥ 80 years, 62.8%; 65-79 years, 51.3%; 20-64 years, 56.2%). CONCLUSION: While patients ≥ 80 years old have a less favorable prognosis than patients <65 years old, the survival rates of patients ≥ 80 years old are not significantly different from the 65- to 79-year-old cohort. After controlling for non-cancer-related death, patients ≥ 80 years old appear to have similar 5-year survival outcomes compared with other patients.


Assuntos
Carcinoma de Células Escamosas/cirurgia , Neoplasias Laríngeas/cirurgia , Terapia de Salvação/métodos , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Carcinoma de Células Escamosas/mortalidade , Carcinoma de Células Escamosas/radioterapia , Feminino , Humanos , Neoplasias Laríngeas/radioterapia , Masculino , Falha de Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...